JP2018508474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508474A5 JP2018508474A5 JP2017535799A JP2017535799A JP2018508474A5 JP 2018508474 A5 JP2018508474 A5 JP 2018508474A5 JP 2017535799 A JP2017535799 A JP 2017535799A JP 2017535799 A JP2017535799 A JP 2017535799A JP 2018508474 A5 JP2018508474 A5 JP 2018508474A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl group
- group
- hydrogen atom
- compound
- double bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14200543.8A EP3040075B1 (en) | 2014-12-30 | 2014-12-30 | C-19 steroids for inhibiting neovascularization |
| EP14200543.8 | 2014-12-30 | ||
| PCT/EP2015/080762 WO2016107778A1 (en) | 2014-12-30 | 2015-12-21 | C-19 steroids for inhibiting neovascularization |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508474A JP2018508474A (ja) | 2018-03-29 |
| JP2018508474A5 true JP2018508474A5 (enExample) | 2019-10-10 |
| JP6788592B2 JP6788592B2 (ja) | 2020-11-25 |
Family
ID=52146363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535799A Expired - Fee Related JP6788592B2 (ja) | 2014-12-30 | 2015-12-21 | 血管新生阻害用ｃ−１９ステロイド |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10426785B2 (enExample) |
| EP (2) | EP3040075B1 (enExample) |
| JP (1) | JP6788592B2 (enExample) |
| KR (1) | KR102481553B1 (enExample) |
| CN (2) | CN107206010B (enExample) |
| CA (1) | CA2972324C (enExample) |
| DK (1) | DK3040075T3 (enExample) |
| EA (2) | EA202190993A3 (enExample) |
| ES (1) | ES2651442T3 (enExample) |
| HR (1) | HRP20171875T1 (enExample) |
| HU (1) | HUE037698T2 (enExample) |
| NO (1) | NO3040075T3 (enExample) |
| PL (1) | PL3040075T3 (enExample) |
| PT (1) | PT3040075T (enExample) |
| RS (1) | RS56621B1 (enExample) |
| SI (1) | SI3040075T1 (enExample) |
| WO (1) | WO2016107778A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3632445A1 (en) | 2018-10-04 | 2020-04-08 | Curadis GmbH | Combinations with a c-19 steroid for treating cancers |
| CN114149923B (zh) * | 2021-11-19 | 2024-03-08 | 大连理工大学 | 内皮细胞-平滑肌细胞共培养的单流道微芯片模型的构建方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| RS20150135A1 (sr) * | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| JP2007529426A (ja) * | 2004-03-12 | 2007-10-25 | エントレメッド インコーポレイテッド | 抗血管新生薬 |
| US20060264413A1 (en) * | 2005-04-18 | 2006-11-23 | Sri International | Method and composition for inhibiting cell proliferation and angiogenesis |
| EP1854465A1 (en) | 2006-05-12 | 2007-11-14 | Alexander Tobias Teichmann | Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
| EP2060300B1 (en) * | 2007-11-13 | 2015-04-15 | Curadis GmbH | C-19 steroids for therapeutic uses |
| CN101619089B (zh) * | 2009-07-28 | 2011-07-20 | 陈大刚 | 抗肿瘤药物cl168、其合成方法及应用 |
-
2014
- 2014-12-30 ES ES14200543.8T patent/ES2651442T3/es active Active
- 2014-12-30 DK DK14200543.8T patent/DK3040075T3/en active
- 2014-12-30 PL PL14200543T patent/PL3040075T3/pl unknown
- 2014-12-30 PT PT142005438T patent/PT3040075T/pt unknown
- 2014-12-30 EP EP14200543.8A patent/EP3040075B1/en active Active
- 2014-12-30 HU HUE14200543A patent/HUE037698T2/hu unknown
- 2014-12-30 NO NO14200543A patent/NO3040075T3/no unknown
- 2014-12-30 RS RS20171258A patent/RS56621B1/sr unknown
- 2014-12-30 SI SI201430519T patent/SI3040075T1/en unknown
-
2015
- 2015-12-21 US US15/535,461 patent/US10426785B2/en active Active
- 2015-12-21 JP JP2017535799A patent/JP6788592B2/ja not_active Expired - Fee Related
- 2015-12-21 CA CA2972324A patent/CA2972324C/en active Active
- 2015-12-21 EP EP15817308.8A patent/EP3215161A1/en not_active Withdrawn
- 2015-12-21 KR KR1020177018043A patent/KR102481553B1/ko active Active
- 2015-12-21 CN CN201580071870.0A patent/CN107206010B/zh not_active Expired - Fee Related
- 2015-12-21 EA EA202190993A patent/EA202190993A3/ru unknown
- 2015-12-21 WO PCT/EP2015/080762 patent/WO2016107778A1/en not_active Ceased
- 2015-12-21 CN CN202110416346.XA patent/CN113117089A/zh active Pending
- 2015-12-21 EA EA201791209A patent/EA039485B1/ru unknown
-
2017
- 2017-12-04 HR HRP20171875TT patent/HRP20171875T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goradel et al. | Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence | |
| Maffucci et al. | Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects | |
| Luo et al. | Peiminine inhibits the IL-1β induced inflammatory response in mouse articular chondrocytes and ameliorates murine osteoarthritis | |
| WO2018215795A2 (en) | Senolytic compounds | |
| EA016653B1 (ru) | Способы и композиции для ингибирования ангиогенеза | |
| Amino et al. | YM-201627: An orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation | |
| JP2005502579A (ja) | 新生血管形成に関連する状態を処置するための方法および組成物 | |
| Ni et al. | Alkaloid derivative ION-31a inhibits breast cancer metastasis and angiogenesis by targeting HSP90α | |
| Guan et al. | Lentinan regulates the immune efficacy of macrophage for lung metastasis in triple negative breast | |
| JP2018508474A5 (enExample) | ||
| Chiang et al. | MART-10, the new brand of 1α, 25 (OH) 2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro | |
| JP6788592B2 (ja) | 血管新生阻害用ｃ−１９ステロイド | |
| CN115813892B (zh) | 原儿茶醛与达卡巴嗪的药物联合及其在治疗恶性黑色素瘤中的用途 | |
| Berk et al. | 593 Krafft temperature of surfactants in vehicles for roflumilast and pimecrolimus cream and effects on skin tolerability | |
| Lee et al. | Isolinderalactone inhibits glioblastoma cell supernatant-induced angiogenesis | |
| Chang et al. | Isoxanthohumol reduces neointimal hyperplasia through the apelin/AKT pathway | |
| US9216163B2 (en) | Method of inhibiting angiogenesis | |
| KR20130075191A (ko) | 세드롤 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 암의 예방 및 치료용 약학적 조성물 | |
| Bridoux et al. | Pro-and anti-angiogenic agents | |
| Boateng et al. | 590 Biological and in-silico characterization of pyrazole and pyrazolone derivatives: Identifies novel anti-skin cancer, antioxidant and tyrosinase inhibitory agents | |
| Song et al. | 595 In vitro evaluation of skin distribution and human dermal papilla cells proliferation for minoxidil 5% topical lotion hydrogel | |
| Keßler et al. | P11. 28 Alteration of blood brain barrier (BBB) permeability by Tumor Treating Fields (TTFields) in vivo | |
| EA044482B1 (ru) | Комбинация для ингибирования пролиферации эндотелиальных клеток | |
| Martinez-Calle et al. | The Role of HNF4α in CKD Progression: PO0604 | |
| Wang et al. | P11. 30 Special VEGF90kDa form in exosome from GBM cells activates TAZ in endothelial cells to promote angiogenesis and contributes bevacizumab resistance |